

The Secretary
Expert Committee on the Selection and Use of
Essential Medicines Innovation, Access and Use
Department of Essential Medicines and Health Products
World Health Organization
E-mail: emlsecretariat@who.int

February 2019

Re: Mifepristone - misoprostol - EML

Dear Secretary

Family Planning NSW is one of Australia's leading providers of reproductive and sexual health services. We are experts on reproductive and sexual health and have provided independent, not for profit clinical services and health information to people throughout New South Wales, Australia's most populous state, since 1926.

I am writing on behalf of Family Planning NSW to support the following proposed changes to the EML listing for mifepristone – misoprostol:

1. Move mifepristone-misoprostol from the Complementary to Core Model List of Essential Medicines
2. Remove the asterisk that states that close medical supervision is required for administration of mifepristone-misoprostol for medical abortion
3. Include dosage form for combi-pack containing: mifepristone 200 milligram tablet and misoprostol 200 microgram tablet
4. Remove the statement "Where permitted under national law and where culturally acceptable"

We support these changes on the basis of international and Australian evidence supporting the safety and efficacy of mifepristone-misoprostol, and on the basis of human rights principals, including increasing women's access to reproductive health care.

Yours sincerely



Adjunct Professor Ann Brassil, CEO

